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Hospitals Albuquerque, New Mexico, United States.Development of neurotrophic peptidergic drugs that can mimic neurotrophins and promote neuro-
genesis and maturation of newborn cells into mature functional neurons represents an exciting
therapeutic opportunity for treatment of Alzheimer disease and other learning and memory disor-
ders as well as enhancing cognition of normal individuals. Here we report the design of a peptidergic
compound, Ac-DGGLAG-NH2, called P21, when administered peripherally, enhanced learning as well
as both short-term and spatial reference memories of normal adult C57Bl6 mice. P21 induced
enhancement of neurogenesis and maturation of newly born neurons in the granular cell layer
and subgranular zone of the dentate gyrus.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
As life expectancy in industrialized countries has been increas-
ing by two years per decade in the last 20 years and is predicted to
further surge, age-associated dementias like Alzheimer disease
(AD) are becoming more and more heavy medical, economic, and
social burden in modern society. AD affects over ﬁve million in
the US and over twenty million worldwide. AD is the most preva-
lent dementia, followed by vascular dementia and dementia with
Lewy bodies. AD has an average progression of 7–10 years, and is
both multifactorial and heterogeneous. Despite AD being a severe
public health problem, no neuroprotective and speciﬁc treatmentchemical Societies. Published by E
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Iqbal).
iana State University Health
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ustus-Liebig-University, Hein-
University of New Mexicois yet available. Numerous targets for pharmacological therapies
of AD are currently under investigation [1].
To maintain or even restore cognitive health and memory is the
ultimate goal in the treatment of dementia. Cerebrolysin (EBEWE
Pharma, Unterach, Austria), a preparation of peptides and amino
acids produced by standardized enzymatic digestion of porcine
brain protein, has been shown to improve memory in patients with
mild to moderate cognitive impairment [2,3]. This drug has also
been shown to display neurotrophic activity in vitro [4,5] and in
animal models of neurodegeneration [6,7]. Cerebrolysin enhances
dentate gyrus (DG) neurogenesis in normal adult rats [8] and an
APP transgenic model of AD [9].
The neurogenic effect of Cerebrolysin might be based upon the
action of peptides in the preparation that are proteolytic products
of neurotrophic factors. In a previous study, we found that Cerebr-
olysin contains peptides which react with neutralizing antibodies
to human CNTF, GDNF, IGF-1 and IGF-2. More speciﬁcally, the CNTF
neutralizing antibody can inhibit the neurogenic effects of Cerebr-
olysin [5]. Based on epitope mapping of neutralizing antibodies to
human CNTF, we found that an 11-mer peptide; Peptide 6 (Ac-
VGDGGLFEKKL-NH2) and a subsequence of it, Peptide 6c (Ac-
DGGL-NH2), enhanced hippocampus-dependent learning and
memory, increased neurogenesis and neuronal plasticity in normal
adult mice [10,11]. Although peptides in general are readily bio-
available, systemic degradation through proteases and relativelylsevier B.V. All rights reserved.
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rendering peptides ‘‘druggable”. To address these design goals,
we added adamantane building blocks to the C-terminus or both
C- and N-termini of Peptide 6c. These bulky, highly lipophilic tricy-
clic alkane building blocks can increase the BBB permeability of
peptides and block enzymatic degradation through exopeptidases.
In the present study, we show that when administered peripher-
ally to normal adult mice, the pentamer Ac-DGGLAG-NH2, called
P21, signiﬁcantly enhanced cognition, increased proliferation and
neuronal differentiation of adult hippocampal progenitors and pro-
moted the expression of synaptic vesicle proteins, synaptophysin
and synapsin I.
2. Materials and methods
Fig. 1 shows the design and structures of peptidergic com-
pounds employed in this study. For synthesis of peptidergic com-
pounds incorporating adamantane building blocks, compounds
P21(Ac-DGGLAG-NH2) and P22 (1-Ad-CO-DGGLAG-NH2), animals
and housing, one trial object recognition test, spatial reference
memory task in the water maze, immunohistochemistry, cell
counts by stereology, analysis of the mechanism of action of P21Fig. 1. Design and structures of neurogenic peptidergic compounds incorporating adam
(Peptide 6) a truncated, still neurogenic tetramer Ac-DGGL-NH2 (Peptide 6c) was designe
this subsequence via solid phase peptide synthesis methods produced Ac-DGGLAG-NH2 (
1-AdCO-DGGLAG-NH2 (P22).through LIF receptor in HepG2 cells, and statistical analysis, see
Supplementary data.
3. Results
3.1. Effect of peptides incorporating adamantane on cognitive function
in normal adult mice
3.1.1. General behavioral observations
Administration of the full-length CNTF protein in human clini-
cal trials is known to cause anorexia, skeletal muscle loss, hyperal-
gesia, cramps, and muscle pain [12,13]. However, in the present
study, we did not observe any alteration in either general physical
state, body weight (Fig. 2A), exploratory behavior (Fig. 2C) or swim
speed (Fig. 2D) during the period of the study, suggesting that
treatment with compound P21 or P22 did not induce any apparent
side-effects. In the water maze task, we did not observe any ﬂoat-
ing behavior suggesting that animals treated with P21 or P22 did
not present any sign of depression or locomotor impairment. The
only general behavioral characteristic P21 and P22 altered was
the level of anxiety of the mice. As shown in Fig. 2B, mice treated
with P21 or P22 spent more time in the center of the open ﬁeldantane building blocks. From the neurogenic undecamer Ac-VGDGGLFEKKL-NH2
d. Addition of an unnatural amino acid based upon adamantane to the C-terminus of
P21); capping of the N-terminus of P21 with adamantane-1-carboxylic acid yielded
Fig. 2. Peptides incorporating AGly improve cognition. P21 and P22 did not induce any effect on body weight (A), exploratory activity (C) or swim speed (D) but reduced
anxiety level of mice (B). (E–F) P21 signiﬁcantly improved the ability to discriminate a new object versus a familiar object. *P < 0.05; Student t-test. (G) P21 and P22 increased
performance in the learning of spatial memory task in water maze. **P < 0.001; two-way ANOVA with post hoc Fisher LSD test. (H) P21 improved performance in the ﬁrst
probe trial (PT1), but treatment with P21 showed no effect 15 days (PT2) or 30 days (PT3) after the end of the treatment. *P < 0.05; Student t-test.
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levels of anxiety.
3.1.2. One-trial object recognition task
To examine short-term memory, we conducted a one-trial ob-
ject recognition task. Mice treated with P21 clearly spent more
time exploring the new object than the familiar object whereas
other groups did not (Fig. 2E). The percentage of discrimination
for animals treated with P21 was signiﬁcantly increased compared
to other groups (P < 0.05, Student t-test; Fig. 2F).
3.1.3. Spatial reference memory task
To investigate potential effects of P21 and P22 on hippocampal
dependent memory, we conducted a spatial reference memory
task in the water maze. Animals from all groups learned well, asevident by signiﬁcantly declining escape latencies across training
sessions (P < 0.05, two-way ANOVAs; Fig. 2G). However, perfor-
mance of mice treated with P21 or P22 improved signiﬁcantly fas-
ter than placebo-treated animals. Escape latencies to reach the
submerged platform were signiﬁcantly reduced for groups treated
with P21 or P22 compared to control group from training day 2–4
(P < 0.01, two-way ANOVA and post hoc Fisher LSD test).
To evaluate the accuracy and the strength of the platform coor-
dinates encoding, we performed probe trials and measured the
time animals spent looking for the platform in the target quadrant.
We ﬁrst carried out a probe trial 24 h after the last day of training.
Then, to evaluate remote memory, we performed probe trials 15
and 30 days after the training and the end of the chronic treatment.
Analysis of retention of memory in the three probe trials conﬁrmed
that all animals had correctly encoded the platform location during
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for it in the target quadrant (Fig. 2H). During the ﬁrst probe trial,
animals treated with P21 focused signiﬁcantly more on the target
quadrant compared to control animals (P < 0.05, Student t-test).
However, this beneﬁcial effect disappeared on day 15 and day 30
washout periods after the end of the treatment with the peptide.
No statistically signiﬁcant effect of P22 was observed in the probe
trials.
Overall, results from the object recognition task and the spatial
reference memory task show that P21 induced positive effects on
cognition.
3.1.4. Enhancement of neurogenesis in the DG
Because neurogenesis is thought to have an important role in
memory and associated learning [14–16], we investigated poten-
tial changes induced by chronic treatment with P21 and P22.
Quantitative evaluation of neurogenesis in the DG revealed a
signiﬁcant increase of BrdU positive cells in the granule cell layer
(GCL) and subgranular zone (SGZ) of animals treated with P21
(P < 0.05, two-way ANOVA and post hoc Fisher LSD test; Fig. 3A
and B). No signiﬁcant alteration in neurogenesis was observed in
the group treated with P22 (Fig. 3A and B).
To estimate net neurogenesis, we next examined the expression
of the marker for mature neurons, NeuN, in the BrdU positive cells
in the DG. A signiﬁcant increase of the number of BrdU/NeuN po-
sitive cells was observed in the DG of mice treated with P21 dueFig. 3. Compound P21 promotes neurogenesis in the DG. (A) Representative picture of do
(B) Numbers of BrdU positive cells were signiﬁcantly increased in P21 treated animals
number of BrdU/NeuN positive cells in the GCL and in the total DG. *P < 0.05, two- wayto a signiﬁcant increase in BrdU/NeuN positive cells in the GCL
(P < 0.05, two-way ANOVA and post hoc Fisher LSD test; Fig. 3A
and C). No signiﬁcant changes were observed in the group of ani-
mals treated with P22.
3.1.5. Enhancement of synaptic plasticity
Synapses are critical components of the neural mechanisms
underlying learning and memory. In order to investigate whether
P21 and P22 have neurotrophic effects, we measured the expres-
sion of two synaptic vesicle proteins; synaptophysin and synapsin I.
Signiﬁcant increases of synaptophysin and synapsin I immu-
noreactivities were observed in the GCL and molecular cell layer
(MCL) of animals treated with P21 (P < 0.001, two-way ANOVA
and post hoc Fisher LSD test; Fig. 4A and B). Animals treated with
P22 expressed similar levels of immunoreactivity of synaptophysin
and synapsin I as did untreated control animals.
3.1.6. Antagonistic effect of P21 on LIF signaling
To investigate whether P21 affects LIF signaling pathway, we
treated HepG2 cells with different concentrations of P21 from
0.01 to 1000 nM along with 0.25 nM LIF for 15 min, and then mea-
sured STAT3 phosphorylation by Western blots. We observed that
LIF-induced STAT3 phosphorylation was inhibited slightly in a
dose-dependent manner. In HepG2 cells, 10 nM of P21 inhibited
30% of LIF-induced phosphorylation of STAT3 (P < 0.005, Student
t-test; Fig. 5).uble labeled BrdU (red) and NeuN (green) positive cells. Scale bar represents 20 lm.
in the total DG, GCL and in the SGZ (C) P21 treatment signiﬁcantly increased the
ANOVA and post hoc Fisher LSD test.
Fig. 4. Compound P21 promotes synaptic plasticity in the DG. P21 signiﬁcantly promoted expression of synaptophysin (A) and synapsin I (B) in the GCL and the MCL of the
DG. ***P < 0.001, two-way ANOVA and post hoc Fisher LSD test. Scale bars represent 100 lm.
Fig. 5. Inhibition of LIF-induced STAT3 phosphorylation by P21 in a dose-depen-
dent manner in HepG2 cells. HepG2 cells were treated with different concentrations
of P21 together with 0.25 nM LIF for 15 min, and then the STAT3 phosphorylation at
Tyr705 (pY-STAT3) was determined by Western blots. The pY-STAT3 value was
normalized to total STAT3 expression. Data are presented as percentages of the
value from cells treated with 0.25 nM LIF alone (100%). *P < 0.05; **P < 0.01.
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Neurotrophic factors are critical for neuronal differentiation,
maturation, and survival, but in the AD brain, the balance of neu-
rotrophic factors is disturbed. Level of basic ﬁbroblast growth fac-
tor is upregulated, whereas the levels of brain-derivedneurotrophic factor and neurotrophin 4 are reduced in the hippo-
campus, the frontal cortex and the parietal cortex (for review,
see [17]. Because they are crucial to maintain a healthy neuronal
microenvironment, neurotrophins generated excitement over the
past decades as therapeutic targets for AD and other dementias.
However, inconvenient pharmacokinetics and adverse side-effect
proﬁles have limited clinical utilization of neurotrophic factors
[18]. Therefore, chemically modiﬁed short peptides able to mimic
positive characteristics of neurotrophic factors represent an oppor-
tunity to circumvent these obstacles.
Derivatives of the diamondoid C10H16 hydrocarbon adamantane
have already been commercialized as antivirals (amantadine,
rimantadine) and as central nervous system active drugs. Nowa-
days, the aminoadamantane Memantine is the only drug pre-
scribed for moderate to severe cases of AD. Based on the
physicochemical and pharmacological properties of drugs incorpo-
rating the adamantane motif, an adamantane-based moiety has
been used as a drug carrier for poorly absorbed compounds,
including peptides, active towards the central nervous system
[19,20]. In a previous study, we demonstrated the beneﬁcial effect
of a CNTF-based tetrapeptide, Peptide 6c, on hippocampus-depen-
dent memory in normal adult mice [11]. We hypothesized that
adding lipophilic groups to Peptide 6c could increase its biostabil-
ity and BBB permeability and consequently enhance its neurotro-
phic, neuroplastic, and cognitive enhancement activities. We
attached the rigid, bulky, and highly lipophilic, unnatural 3-amino-
adamantane-1-carboxylic acid (‘‘AGly”) C-terminally to the Peptide
6c to produce compound P21. The rigidity of the -amino acid AGly
should block the carboxypeptidase activity, thereby stabilizing
Peptide 6c in vivo [21]. Enhancing the overall lipophilicity of Pep-
tide 6c should boost its ability to cross the BBB. By capping the N-
terminus of the sequence of Peptide 6c with adamantane-1-car-
boxylic acid in P22, we speculated that it would further increase
lipophilicity and BBB penetration as well as resistance against ami-
nopeptidase activity.
In AD, the hippocampus is the most vulnerable brain region to
neurodegeneration [22]. Moreover, hippocampus-dependent cog-
nitive impairments are associated with synaptic loss [23] which
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physin in the hippocampus correlates with cognitive decline in AD
patients [25] and with decreased synaptic activity in several mouse
models of AD [26,27]. Therefore, in the present study we investi-
gated effects of compounds P21 and P22 on hippocampus-depen-
dent cognitive functions and on hippocampal synaptic plasticity.
In the present study, P21 signiﬁcantly enhanced two different
cognitive mechanisms; an object recognition task and a spatial ref-
erence memory task. The one-trial object recognition task is
thought to critically depend on the entorhinal cortex, hippocampus
and frontal cortex [28–31]. In the present study we observed that
control animals as well as animals treated with P22 did not prefer-
entially explore the novel object. This null preference did not re-
ﬂect a lack of interest for novelty but rather enhanced attraction
for familiarity [32]. This reveals that, for control and P22-treated
animals, familiar object representation is yet to be built and ﬁnal-
ized, therefore requiring as much attention as the novel object to
complete the encoding. On the contrary, animals treated with
P21 displayed a marked preference for the novel object. This sug-
gests that the representation of the familiar object has been fully
encoded, and then was not anymore a subject of attention at the
expense of the novel stimulus. These results showed that P21
treatment accelerated the encoding of object representation, thus,
in the present experimental condition, improved short-term mem-
ory performance.
In the spatial reference memory task, the hippocampal system
processes information about the relationships among distal envi-
ronmental cues into a spatial map where spatial coordinates of
the submerged platform are encoded [33]. The hippocampus is also
crucial for memory storage, consolidation and restitution of the
spatial information [34]. In the present study, we observed that
both P21 and P22 increased the learning of the task suggesting that
both peptides strengthened processing of the spatial environment.
However, only P21 positively enhanced performances in the probe
trial. This shows that the beneﬁcial effect of P21 on encoding, stor-
age, and consolidation of the spatial information during the treat-
ment period is stronger than of P22.
Examining hippocampal synaptic activity, we next found that
P21 induced signiﬁcant increase in synaptophysin and synapsin I
immunoreactivity in the DG. Synaptophysin is a glycoprotein of
the presynaptic vesicles [35] involved in the vesicle trafﬁcking
machinery [36] by regulating synaptic vesicle exocytosis [37]. Be-
sides, Synapsin I is a neuro-speciﬁc phosphoprotein highly concen-
trated in presynaptic nerve terminals, where, associated with the
cytoplasmic surface of the synaptic vesicle, it plays a key role in
neurotransmitter release [38]. We observed that P21 positively en-
hanced synaptophysin and synapsin I levels. This suggests that P21
had a beneﬁcial effect on synaptic plasticity by increasing the pre-
synaptic release of neurotransmitters. We speculate that this aug-
mentation of neurotransmitters in the synaptic cleft potentiates
post-synaptic excitability, subsequently enhancing the efﬁcacy of
the neuronal network taking charge of stimulus processing to en-
code, store or recall information.
The contribution of adult hippocampal neurogenesis to mem-
ory has been studied at experimental and theoretical levels. Cur-
rent literature supports the idea that both neural stem cells and
immature neurons play distinct roles in hippocampus-dependent
memory tasks [39]. Newly born mature cells may have an inher-
ent advantage of being recruited into patterns of new memory
networks [40]. In the present work, we observed that P21 in-
creased progenitor cell proliferation as well as neuronal differen-
tiation. Thus, through this neurogenic activity, P21 enhanced the
stock of functional neurons to be potentially recruited into neuro-
nal networks of information processing. This characteristic of P21
might be crucial as a potential treatment for neurodegeneration
since in AD, although proliferation of immature neurons is in-creased, newly generated neurons in the DG do not mature
[41,42].
The present study shows that P21 induces neuronal plasticity
and neurogenic properties which consequently enhance cognition.
In particular, we have investigated the effects of P21 in the hippo-
campus, but, considering positive enhancement of the object rec-
ognition task which involves other brain structures as well as the
hippocampus, we speculate that the beneﬁcial effect of P21 we
have shown to be connected with neuronal plasticity in the DG
may occur in other brain areas as well.
In previous work we showed that Peptide 6 contains a putative
leukemia inhibitory factor receptor-binding sequence of CNTF and
interferes with the signal transduction of LIF more than with that
of CNTF [10]. Because LIF inhibits neurogenesis in the DG [43–
45], we hypothesized that Peptide 6 enhances neurogenesis
through the CNTF pathway, inducing a partial inhibition of LIF.
The present study shows that P21 acts as its parent molecule, the
11-mer peptide, partially inhibiting LIF activity through the STAT3
pathway. Because we did not observe conclusive effects of the clo-
sely related derivative P22, which differs in the N-terminal acyla-
tion, on cognition, neuronal plasticity and neurogenesis, we
assume that incorporating an additional adamantane moeity in-
stead of the smaller N-acetyl group at the N-terminus of P21 to fur-
nish P22, probably prevented a proper interaction of the active –
DGGL– subsequence with its receptors.
Overall, in the present study we have shown that the CNTF-de-
rived peptidergic compound, P21, incorporating a c-aminoada-
mantane-1-carboxylic acid at its C-terminus, is neurogenic and
neuroplastic and enhances cognition in normal adult mice. It is
important to note that demonstrating positive effects of the stud-
ied peptides is a challenging task because it is difﬁcult to observe
enhancement of cognition due to ceiling effects in normal adult
mice we have used previously. Although we previously observed
beneﬁcial effects of the CNTF tetra peptide, Peptide 6c, on memory
[11], the improvements in object recognition and spatial reference
memory we report here for the pentamer P21 are more pro-
nounced. We thus conclude that the lipophillically modiﬁed,
CNTF-derived pentamer P21 is an attractive candidate for the
development of pro-cognitive drugs to prevent and treat learning
and memory disorders and neurodegenerative diseases such as AD.
Acknowledgements
We are grateful to Mrs. Janet Murphy for secretarial assistance.
This work was supported in part by theNew York State Ofﬁce of
Mental Retardation and Developmental Disabilities; EVER Neuro-
Pharma, Unterach, Austria; and the T.L.L. Temple Foundation Dis-
covery Award for Alzheimer Disease Research, the Alzheimer
Association, Chicago, IL. We thank Dr. Boris Arshava and the Naider
Group at the Chemistry Department of the College of Staten Island
for assistance with peptide puriﬁcation and analysis.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.06.025.
References
[1] Iqbal, K. and Grundke-Iqbal, I. (2007) Developing pharmacological therapies
for Alzheimer disease. Cell. Mol. Life Sci. 64, 2234–2244.
[2] Ruther, E., Ritter, R., Apecechea, M., Freytag, S., Gmeinbauer, R. and Windisch,
M. (2000) Sustained improvements in patients with dementia of Alzheimer’s
type (DAT) 6 months after termination of Cerebrolysin therapy. J. Neural.
Transm. 107, 815–829.
[3] Alvarez, X.A. et al. (2006) A 24-week, double-blind, placebo-controlled study
of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s
disease. Eur. J. Neurol. 13, 43–54.
B. Li et al. / FEBS Letters 584 (2010) 3359–3365 3365[4] Mallory, M., Honer, W., Hsu, L., Johnson, R., Rockenstein, E. and Masliah, E.
(1999) In vitro synaptotrophic effects of Cerebrolysin in NT2N cells. Acta
Neuropathol. 97, 437–446.
[5] Chen, H., Tung, Y.C., Li, B., Iqbal, K. and Grundke-Iqbal, I. (2007) Trophic factors
counteract elevated FGF-2-induced inhibition of adult neurogenesis.
Neurobiol. Aging 28, 1148–1162.
[6] Francis-Turner, L. and Valouskova, V. (1996) Nerve growth factor and
nootropic drug Cerebrolysin but not ﬁbroblast growth factor can reduce
spatial memory impairment elicited by ﬁmbria–fornix transection: short-term
study. Neurosci. Lett. 202, 193–196.
[7] Masliah, E., Armasolo, F., Veinbergs, I., Mallory, M. and Samuel, W. (1999)
Cerebrolysin ameliorates performance deﬁcits, and neuronal damage in
apolipoprotein E-deﬁcient mice. Pharmacol. Biochem. Behav. 62, 239–245.
[8] Tatebayashi, Y., Lee, M.H., Li, L., Iqbal, K. and Grundke-Iqbal, I. (2003) The
dentate gyrus neurogenesis: a therapeutic target for Alzheimer’s disease. Acta
Neuropathol. (Berl) 105, 225–232.
[9] Rockenstein, E., Mante, M., Adame, A., Crews, L., Moessler, H. and Masliah, E.
(2007) Effects of Cerebrolysin on neurogenesis in an APP transgenic model of
Alzheimer’s disease. Acta Neuropathol. 113, 265–275.
[10] Chohan, M.O., Li, B., Blanchard, J., Tung, Y.C., Heaney, A.T., Rabe, A., Iqbal, K. and
Grundke-Iqbal, I. (2009). Enhancement of dentate gyrus neurogenesis,
dendritic and synaptic plasticity and memory by a neurotrophic peptide.
Neurobiol. Aging, Epub ahead of print, Sept. 2009.
[11] Blanchard, J., Chohan, M.O., Li, B., Liu, F., Iqbal, K. and Grundke-Iqbal, I. (2010).
Beneﬁcial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis,
neuronal plasticity and spatial memory in mice. J. Alzheimer’s Dis., in press.
[12] SG, A.C.T. (1996) A double-blind placebo-controlled clinical trial of
subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in
amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology
46, 1244–1249.
[13] Windisch, M., Gschanes, A. and Hutter-Paier, B. (1998) Neurotrophic activities
and therapeutic experience with a brain derived peptide preparation. J.
Neural. Transm. Suppl. 53, 289–298.
[14] Gould, E., Beylin, A., Tanapat, P., Reeves, A. and Shors, T.J. (1999) Learning
enhances adult neurogenesis in the hippocampal formation. Nat. Neurosci. 2,
260–265.
[15] Shors, T.J., Miesegaes, G., Beylin, A., Zhao, M., Rydel, T. and Gould, E. (2001)
Neurogenesis in the adult is involved in the formation of trace memories.
Nature 410, 372–376.
[16] Snyder, J.S., Hong, N.S., McDonald, R.J. and Wojtowicz, J.M. (2005) A role for
adult neurogenesis in spatial long-term memory. Neuroscience 130, 843–852.
[17] Schindowski, K., Bretteville, A., Leroy, K., Begard, S., Brion, J.P., Hamdane, M.
and Buee, L. (2006) Alzheimer’s disease-like tau neuropathology leads to
memory deﬁcits and loss of functional synapses in a novel mutated tau
transgenic mouse without any motor deﬁcits. Am. J. Pathol. 169, 599–616.
[18] Price, R.D., Milne, S.A., Sharkey, J. and Matsuoka, N. (2007) Advances in small
molecules promoting neurotrophic function. Pharmacol. Ther. 115, 292–306.
[19] Kitagawa, K., Mizobuchi, N., Hama, T., Hibi, T., Konishi, R. and Futaki, S. (1997)
Synthesis and antinociceptive activity of [D-Ala2]Leu-enkephalin derivatives
conjugated with the adamantane moiety. Chem. Pharm. Bull. (Tokyo) 45,
1782–1787.
[20] Tsuzuki, N., Hama, T., Hibi, T., Konishi, R., Futaki, S. and Kitagawa, K. (1991)
Adamantane as a brain-directed drug carrier for poorly absorbed drug:
antinociceptive effects of [D-Ala2]Leu-enkephalin derivatives conjugated with
the 1-adamantane moiety. Biochem. Pharmacol. 41, R5–R8.
[21] Frackenpohl, J., Arvidsson, P.I., Schreiber, J.V. and Seebach, D. (2001) The
outstanding biological stability of beta- and gamma-peptides toward
proteolytic enzymes: an in vitro investigation with ﬁfteen peptidases.
ChemBioChem 2, 445–455.
[22] Hyman, B.T., Van Hoesen, G.W., Damasio, A.R. and Barnes, C.L. (1984)
Alzheimer’s disease: cell-speciﬁc pathology isolates the hippocampal
formation. Science 225, 1168–1170.
[23] Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen,
L.A. and Katzman, R. (1991) Physical basis of cognitive alterations inAlzheimer’s disease: synapse loss is the major correlate of cognitive
impairment. Ann. Neurol. 30, 572–580.
[24] Masliah, E., Honer, W.G., Mallory, M., Voigt, M., Kushner, P., Hansen, L. and
Terry, R. (1994) Topographical distribution of synaptic-associated proteins in
the neuritic plaques of Alzheimer’s disease hippocampus. Acta Neuropathol.
87, 135–142.
[25] Sze, C.I., Bi, H., Kleinschmidt-DeMasters, B.K., Filley, C.M. and Martin, L.J.
(2000) Selective regional loss of exocytotic presynaptic vesicle proteins in
Alzheimer’s disease brains. J. Neurol. Sci. 175, 81–90.
[26] Hsia, A.Y. et al. (1999) Plaque-independent disruption of neural circuits in
Alzheimer’s disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228–3233.
[27] Lanz, T.A., Carter, D.B. and Merchant, K.M. (2003) Dendritic spine loss in the
hippocampus of young PDAPP and Tg2576 mice and its prevention by the
ApoE2 genotype. Neurobiol. Dis. 13, 246–253.
[28] Mitchell, J.B. and Laiacona, J. (1998) The medial frontal cortex and temporal
memory: tests using spontaneous exploratory behaviour in the rat. Behav.
Brain Res. 97, 107–113.
[29] Ennaceur, A. and Aggleton, J.P. (1997) The effects of neurotoxic lesions of the
perirhinal cortex combined to fornix transection on object recognition
memory in the rat. Behav. Brain Res. 88, 181–193.
[30] Ennaceur, A., Neave, N. and Aggleton, J.P. (1997) Spontaneous object
recognition and object location memory in rats: the effects of lesions in the
cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the
fornix. Exp. Brain Res. 113, 509–519.
[31] Clark, R.E., Zola, S.M. and Squire, L.R. (2000) Impaired recognition memory in
rats after damage to the hippocampus. J. Neurosci. 20, 8853–8860.
[32] Ennaceur, A. (2010). One-trial objects recognition in rats and mice:
methodological and theoritical issues. Behav. Brain Res., in press.
[33] Morris, R.G., Garrud, P., Rawlins, J.N. and O’Keefe, J. (1982) Place navigation
impaired in rats with hippocampal lesions. Nature 297, 681–683.
[34] Riedel, G. et al. (1999) Reversible neural inactivation reveals hippocampal
participation in several memory processes. Nat. Neurosci. 2, 898–905.
[35] Jahn, R., Schiebler, W., Ouimet, C. and Greengard, P. (1985) A 38 000-dalton
membrane protein (p38) present in synaptic vesicles. Proc. Natl. Acad. Sci. USA
82, 4137–4141.
[36] Janz, R., Sudhof, T.C., Hammer, R.E., Unni, V., Siegelbaum, S.A. and Bolshakov,
V.Y. (1999) Essential roles in synaptic plasticity for synaptogyrin I and
synaptophysin I. Neuron 24, 687–700.
[37] Arthur, C.P. and Stowell, M.H. (2007) Structure of synaptophysin: a hexameric
MARVEL-domain channel protein. Structure 15, 707–714.
[38] Greengard, P., Valtorta, F., Czernik, A.J. and Benfenati, F. (1993) Synaptic
vesicle phosphoproteins and regulation of synaptic function. Science 259,
780–785.
[39] Aimone, J.B., Wiles, J. and Gage, F.H. (2006) Potential role for adult
neurogenesis in the encoding of time in new memories. Nat. Neurosci. 9,
723–727.
[40] Kee, N., Teixeira, C.M., Wang, A.H. and Frankland, P.W. (2007) Preferential
incorporation of adult-generated granule cells into spatial memory networks
in the dentate gyrus. Nat. Neurosci. 10, 355–362.
[41] Li, B., Yamamori, H., Tatebayashi, Y., Shaﬁt-Zagardo, B., Tanimukai, H., Chen, S.,
Iqbal, K. and Grundke-Iqbal, I. (2008) Failure of neuronal maturation in
Alzheimer disease dentate gyrus. J. Neuropathol. Exp. Neurol. 67, 78–84.
[42] Jin, K., Peel, A.L., Mao, X.O., Xie, L., Cottrell, B.A., Henshall, D.C. and Greenberg,
D.A. (2004) Increased hippocampal neurogenesis in Alzheimer’s disease. Proc.
Natl. Acad. Sci. USA 101, 343–347.
[43] Shimazaki, T., Shingo, T. and Weiss, S. (2001) The ciliary neurotrophic factor/
leukemia inhibitory factor/gp130 receptor complex operates in the
maintenance of mammalian forebrain neural stem cells. J. Neurosci. 21,
7642–7653.
[44] Bonaguidi, M.A., McGuire, T., Hu, M., Kan, L., Samanta, J. and Kessler, J.A. (2005)
LIF and BMP signaling generate separate and discrete types of GFAP-
expressing cells. Development 132, 5503–5514.
[45] Bauer, S. and Patterson, P.H. (2006) Leukemia inhibitory factor promotes
neural stem cell self-renewal in the adult brain. J. Neurosci. 26, 12089–12099.
